BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sayiner M, Golabi P, Younossi ZM. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. Dig Dis Sci 2019;64:910-7. [DOI: 10.1007/s10620-019-05537-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 28.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhou J, He X, Wang M, Zhao Y, Wang L, Mao A, Wang L. Enhanced Recovery After Surgery in the Patients With Hepatocellular Carcinoma Undergoing Hemihepatectomy. Surg Innov 2022;:15533506211057628. [PMID: 35238718 DOI: 10.1177/15533506211057628] [Reference Citation Analysis]
2 Ye XR, Pan DB, Wang LF. Expression of miR-145-3p in hepatocellular cancer and its regulatory effect on growth of hepatocellular cancer cells. Shijie Huaren Xiaohua Zazhi 2020; 28(17): 827-833 [DOI: 10.11569/wcjd.v28.i17.827] [Reference Citation Analysis]
3 Taye BW, Clark PJ, Hartel G, Powell EE, Valery PC. Remoteness of residence predicts tumor stage, receipt of treatment, and mortality in patients with hepatocellular carcinoma. JGH Open 2021;5:754-62. [PMID: 34263069 DOI: 10.1002/jgh3.12580] [Reference Citation Analysis]
4 Xu P, Ge R. Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy. European Journal of Medicinal Chemistry 2022;230:114118. [DOI: 10.1016/j.ejmech.2022.114118] [Reference Citation Analysis]
5 Kornberg A, Witt U, Schernhammer M, Kornberg J, Müller K, Friess H, Thrum K. The role of preoperative albumin‐bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma. J Surg Oncol 2019;120:1126-36. [DOI: 10.1002/jso.25721] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 Mehta R, Tang Qinghe, Tsilimigras DI, Paredes A, Dillhoff M, Cloyd JM, Ejaz A, Tsung A, Spolverato G, Pawlik TM. Long-term outcomes after resection of alcohol-related versus hepatitis-related hepatocellular carcinoma: A SEER-Medicare database analysis. Am J Surg 2021;222:167-72. [PMID: 33131693 DOI: 10.1016/j.amjsurg.2020.10.033] [Reference Citation Analysis]
7 Ding Y, Sun Z, Zhang S, Han X, Li Y, Xu Q, Zhou L, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Down-regulation of small nuclear RNA (snRNA) RNU5E-1 in hepatocellular carcinoma presents with vital clinical significance. J Gastrointest Oncol 2020;11:738-46. [PMID: 32953157 DOI: 10.21037/jgo-20-49] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Wang X, Chen M, Liang X, Bai Y, Zeng J, Xu X, Li H, Wang J, Fan K, Zhao G. RNF135 Promoter Methylation Is Associated With Immune Infiltration and Prognosis in Hepatocellular Carcinoma. Front Oncol 2022;11:752511. [DOI: 10.3389/fonc.2021.752511] [Reference Citation Analysis]
9 Wang J, Zhao H, Yu J, Xu X, Jing H, Li N, Tang Y, Wang S, Li Y, Cai J, Jin J. MiR-320b/RAD21 axis affects hepatocellular carcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling. Cancer Sci 2021;112:575-88. [PMID: 33251678 DOI: 10.1111/cas.14751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhou J, He X, Wang M, Zhao Y, Zhang N, Wang L, Mao A, Wang L. Enhanced Recovery After Surgery in Patients With Hepatocellular Carcinoma Undergoing Laparoscopic Hepatectomy. Front Surg 2021;8:764887. [PMID: 34881286 DOI: 10.3389/fsurg.2021.764887] [Reference Citation Analysis]
11 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
12 Zhang L, Liu Y, Tao H, Zhu H, Pan Y, Li P, Liang H, Zhang B, Song J. Circular RNA circUBE2J2 acts as the sponge of microRNA-370-5P to suppress hepatocellular carcinoma progression. Cell Death Dis 2021;12:985. [PMID: 34686662 DOI: 10.1038/s41419-021-04269-4] [Reference Citation Analysis]
13 Li X, Yu H, Gong Y, Wu P, Feng Q, Liu C. Fuzheng Xiaozheng prescription relieves rat hepatocellular carcinoma through improving anti-inflammation capacity and regulating lipid related metabolisms. J Ethnopharmacol 2022;284:114801. [PMID: 34748868 DOI: 10.1016/j.jep.2021.114801] [Reference Citation Analysis]
14 Pei S, Chen Z, Tan H, Fan L, Zhang B, Zhao C. SLC16A1-AS1 enhances radiosensitivity and represses cell proliferation and invasion by regulating the miR-301b-3p/CHD5 axis in hepatocellular carcinoma. Environ Sci Pollut Res Int 2020;27:42778-90. [PMID: 32748357 DOI: 10.1007/s11356-020-09998-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Ma D, Wei J, Chen S, Wang H, Ning L, Luo SH, Liu CL, Song G, Yao Q. Fucoidan Inhibits the Progression of Hepatocellular Carcinoma via Causing lncRNA LINC00261 Overexpression. Front Oncol 2021;11:653902. [PMID: 33928038 DOI: 10.3389/fonc.2021.653902] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Cho K, Ro SW, Lee HW, Moon H, Han S, Kim HR, Ahn SH, Park JY, Kim DY. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. Hepatology 2021;74:2605-21. [PMID: 34101869 DOI: 10.1002/hep.32000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
17 Zheng Q, Zhang Q, Yu X, He Y, Guo W. FENDRR: A pivotal, cancer-related, long non-coding RNA. Biomed Pharmacother 2021;137:111390. [PMID: 33761608 DOI: 10.1016/j.biopha.2021.111390] [Reference Citation Analysis]
18 Zhang N, Wang Z, Lv J, Zhang S, Liu Y, Liu T, Li W, Gong L, Zhang X, El-omar EM, Lu W. Characterization of Gut Microbiota and Exploration of Potential Predictive Model for Hepatocellular Carcinoma Microvascular Invasion. Front Med 2022;9:836369. [DOI: 10.3389/fmed.2022.836369] [Reference Citation Analysis]
19 Merle P. Pragmatic tools for the prediction and potential early diagnosis of hepatitis B virus-related hepatocellular carcinoma? Clin Res Hepatol Gastroenterol 2021;45:101722. [PMID: 34146725 DOI: 10.1016/j.clinre.2021.101722] [Reference Citation Analysis]
20 Pu J, Wu X, Wu Y, Shao Z, Luo C, Tang Q, Wang J, Wei H, Lu Y. Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1. Aging (Albany NY) 2021;13:12207-23. [PMID: 33952719 DOI: 10.18632/aging.103797] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Devan AR, Kumar AR, Nair B, Anto NP, Muraleedharan A, Mathew B, Kim H, Nath LR. Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma. Pharmaceuticals (Basel) 2021;14:656. [PMID: 34358082 DOI: 10.3390/ph14070656] [Reference Citation Analysis]
22 Chen M, Zhang B, Topatana W, Cao J, Zhu H, Juengpanich S, Mao Q, Yu H, Cai X. Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning. NPJ Precis Oncol. 2020;4:14. [PMID: 32550270 DOI: 10.1038/s41698-020-0120-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
23 Ion D, Niculescu AG, Păduraru DN, Andronic O, Mușat F, Grumezescu AM, Bolocan A. An Up-to-Date Review of Natural Nanoparticles for Cancer Management. Pharmaceutics 2021;14:18. [PMID: 35056915 DOI: 10.3390/pharmaceutics14010018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wang M, Jiang F, Wei K, Mao E, Yin G, Wu C. Identification of Novel Gene Signature Associated with Cell Glycolysis to Predict Survival in Hepatocellular Carcinoma Patients. J Oncol 2021;2021:5564525. [PMID: 34035809 DOI: 10.1155/2021/5564525] [Reference Citation Analysis]
25 Graf J, Stengel A. Psychological Burden and Psycho-Oncological Interventions for Patients With Hepatobiliary Cancers-A Systematic Review. Front Psychol 2021;12:662777. [PMID: 34025526 DOI: 10.3389/fpsyg.2021.662777] [Reference Citation Analysis]
26 Lin HS, Huang YL, Wang YS, Hsiao E, Hsu TA, Shiao HY, Jiaang WT, Sampurna BP, Lin KH, Wu MS, Lai GM, Yuh CH. Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index than Sorafenib via Zebrafish Drug Screening Platform. Cancers (Basel) 2019;11:E739. [PMID: 31141996 DOI: 10.3390/cancers11060739] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
27 Kronenfeld JP, Ryon EL, Goldberg D, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Livingstone AS, Merchant NB, Goel N. Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study. Ann Surg Oncol 2021;28:1929-36. [PMID: 32975686 DOI: 10.1245/s10434-020-09156-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Shen D, Zhao H, Zeng P, Ge M, Shrestha S, Zhao W. Circular RNA circ_0001459 accelerates hepatocellular carcinoma progression via the miR-6165/IGF1R axis. Ann N Y Acad Sci 2022. [PMID: 35199365 DOI: 10.1111/nyas.14753] [Reference Citation Analysis]
29 Liao W, Huang J, Hutton D, Zhu G, Wu Q, Wen F, Bai L, Li Q. Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma. Liver Int 2019;39:2408-16. [DOI: 10.1111/liv.14257] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
30 Ganesan M, Wang W, Mathews S, Makarov E, New-Aaron M, Dagur RS, Malo A, Protzer U, Kharbanda KK, Casey CA, Poluektova LY, Osna NA. Ethanol attenuates presentation of cytotoxic T-lymphocyte epitopes on hepatocytes of HBV-infected humanized mice. Alcohol Clin Exp Res 2021. [PMID: 34773268 DOI: 10.1111/acer.14740] [Reference Citation Analysis]
31 Jeng KS, Sheen IS, Lin SS, Leu CM, Chang CF. The Role of Endoglin in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3208. [PMID: 33809908 DOI: 10.3390/ijms22063208] [Reference Citation Analysis]
32 He D, Cai L, Huang W, Weng Q, Lin X, You M, Liao S. Prognostic value of fatty acid metabolism-related genes in patients with hepatocellular carcinoma. Aging (Albany NY) 2021;13:17847-63. [PMID: 34257161 DOI: 10.18632/aging.203288] [Reference Citation Analysis]
33 Zhang Y, Zhang Y, Xu H. Effect of Codonopsis pilosula Polysaccharides on the Growth and Motility of Hepatocellular Carcinoma HepG2 Cells by Regulating β -Catenin/TCF4 Pathway. International Journal of Polymer Science 2019;2019:1-7. [DOI: 10.1155/2019/7068437] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Kronenfeld JP, Ryon EL, Goldberg D, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Merchant NB, Goel N. Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis. HPB (Oxford) 2021;23:868-76. [PMID: 33487553 DOI: 10.1016/j.hpb.2020.11.1150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Yousef MH, El-Fawal HAN, Abdelnaser A. Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:9593254. [PMID: 33299889 DOI: 10.1155/2020/9593254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Tang SJ, Yang JB. LncRNA SNHG14 aggravates invasion and migration as ceRNA via regulating miR-656-3p/SIRT5 pathway in hepatocellular carcinoma. Mol Cell Biochem 2020;473:143-53. [PMID: 32607966 DOI: 10.1007/s11010-020-03815-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Gorini F, Bustaffa E, Bolignano D, Cori L, Faita F, Gastaldelli A, Interdonato M, Minichilli F, Quattrone G, Squadrito F, Tripepi G, Vassalle C, Bianchi F. Biomarkers of exposure and early effect in three contaminated sites of southern Italy: protocols for etiological epidemiological studies. BMJ Open 2020;10:e036160. [PMID: 32393613 DOI: 10.1136/bmjopen-2019-036160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Zhu W, Butrin A, Melani RD, Doubleday PF, Ferreira GM, Tavares MT, Habeeb Mohammad TS, Beaupre BA, Kelleher NL, Moran GR, Liu D, Silverman RB. Rational Design, Synthesis, and Mechanism of (3S,4R)-3-Amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic Acid: Employing a Second-Deprotonation Strategy for Selectivity of Human Ornithine Aminotransferase over GABA Aminotransferase. J Am Chem Soc 2022. [PMID: 35293728 DOI: 10.1021/jacs.2c00924] [Reference Citation Analysis]
39 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
40 Ortega JF, Heidor R, Auriemo AP, Affonso JM, D'Amico T, Herz C, de Conti A, Ract J, Gioieli LA, Purgatto E, Lamy E, Pogribny I, Moreno FS. Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis. Carcinogenesis 2021:bgab039. [PMID: 33999989 DOI: 10.1093/carcin/bgab039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Benkerroum N. Retrospective and Prospective Look at Aflatoxin Research and Development from a Practical Standpoint. Int J Environ Res Public Health 2019;16:E3633. [PMID: 31569703 DOI: 10.3390/ijerph16193633] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
42 Mu X, Zhong Y, Zhang X, Qu C, Chen S. Early Diagnosis Value of DCE-MRI Hemodynamic Parameters in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/9556589] [Reference Citation Analysis]
43 Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13:688-694. [PMID: 31701393 DOI: 10.1007/s12072-019-09995-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
44 Abesig J, Chen Y, Wang H, Sompo FM, Wu IXY. Prevalence of viral hepatitis B in Ghana between 2015 and 2019: A systematic review and meta-analysis. PLoS One 2020;15:e0234348. [PMID: 32530945 DOI: 10.1371/journal.pone.0234348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Jin F, Wang R, Zhu Y, Chen J, Cao W, Wang Y, Wu Y, Song X, Huang Y, Dong J, Ren Z. A novel quinolinylmethyl substituted ethylenediamine compound exerts anti-cancer effects via stimulating the accumulation of reactive oxygen species and NO in hepatocellular carcinoma cells. Eur J Pharmacol 2020;885:173497. [PMID: 32841641 DOI: 10.1016/j.ejphar.2020.173497] [Reference Citation Analysis]
46 Butrin A, Butrin A, Wawrzak Z, Moran GR, Liu D. Determination of the pH dependence, substrate specificity, and turnovers of alternative substrates for human ornithine aminotransferase. J Biol Chem 2022;298:101969. [PMID: 35460691 DOI: 10.1016/j.jbc.2022.101969] [Reference Citation Analysis]
47 Ruiz-Margáin A, Román-Calleja BM, Moreno-Guillén P, González-Regueiro JA, Kúsulas-Delint D, Campos-Murguía A, Flores-García NC, Macías-Rodríguez RU. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(10): 1440-1452 [PMID: 34721776 DOI: 10.4251/wjgo.v13.i10.1440] [Reference Citation Analysis]
48 Czajka P, Przybyłkowski A, Nowak A, Postula M, Wolska M, Mirowska-Guzel D, Czlonkowska A, Eyileten C. Antiplatelet drugs and liver fibrosis. Platelets 2021;:1-10. [PMID: 33577391 DOI: 10.1080/09537104.2021.1883574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Xu D, Wang Y, Wu J, Lin S, Chen Y, Zheng J. Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma. Cancer Cell Int 2021;21:621. [PMID: 34819088 DOI: 10.1186/s12935-021-02326-8] [Reference Citation Analysis]
50 Vorobioff JD, Contreras F, Tanno F, Hernández L, Bessone F, Colombato L, Adi J, Fassio E, Felgueres M, Fernández G, Gaite L, Gibelli D, Darrichon HG, Lafage M, Lombardo D, López S, Mateo A, Mendizábal M, Pecoraro J, Ruf A, Ruiz P, Severini J, Stieben T, Sixto M, Zárate F, Barraza SB, Sierra ID, Pacheco VR, Roblero JP, Rojas JO, González PR, Rodríguez DSM, Sierralta A, Manchego AU, Valdes E, Yaquich P, Wolff R, Valdivia FB, Gallegos RC, Galloso R, Marcelo JS, Montes P, Tenorio L, Veramendi I, Alava E, Armijos X, Benalcazar G, Carrera E, Pazmiño GF, Díaz EM, Garassini M, Marrero RP, Infante M, Suárez DP, Gutiérrez JC, Reyes CMV, Serrano YM, Hernández RH, Martínez OM, González TP, Andara MT, Hernández MS, Gerona S, García I, Tijera F, López EP, Torres K, Garzón M. A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management. Ann Hepatol 2020;19:396-403. [PMID: 32418749 DOI: 10.1016/j.aohep.2020.03.007] [Reference Citation Analysis]
51 Elkhamesy A, Refaat M, Gouida MSO, Alrdahe SS, Youssef MM. Diminished CCl4 -induced hepatocellular carcinoma, oxidative stress, and apoptosis by co-administration of curcumin or selenium in mice. J Food Biochem 2021;:e13845. [PMID: 34231234 DOI: 10.1111/jfbc.13845] [Reference Citation Analysis]
52 Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021; 27(17): 2025-2038 [PMID: 34007137 DOI: 10.3748/wjg.v27.i17.2025] [Reference Citation Analysis]
53 Ganesan M, Eikenberry A, Poluektova LY, Kharbanda KK, Osna NA. Role of alcohol in pathogenesis of hepatitis B virus infection. World J Gastroenterol 2020; 26(9): 883-903 [PMID: 32206001 DOI: 10.3748/wjg.v26.i9.883] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
54 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Du M, Feng J, Tao Y, Pan Q, Chen F. GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma. J Healthc Eng 2021;2021:7631815. [PMID: 34900204 DOI: 10.1155/2021/7631815] [Reference Citation Analysis]
56 Wen Tan SL, Israeli E, Ericksen RE, Chow PK, Han W. The altered lipidome of hepatocellular carcinoma. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.004] [Reference Citation Analysis]
57 Rahim MA, Madni A, Tahir N, Jan N, Shah H, Khan S, Ullah R, Bari A, Khan MS. Mild Hyperthermia Responsive Liposomes for Enhanced In Vitro and In Vivo Anticancer Efficacy of Doxorubicin against Hepatocellular Carcinoma. Pharmaceutics 2021;13:1310. [PMID: 34452271 DOI: 10.3390/pharmaceutics13081310] [Reference Citation Analysis]
58 Shen S, Du M, Liu Q, Gao P, Wang J, Liu S, Gu L. Development of GLUT1-targeting alkyl glucoside-modified dihydroartemisinin liposomes for cancer therapy. Nanoscale 2020;12:21901-12. [PMID: 33108431 DOI: 10.1039/d0nr05138a] [Reference Citation Analysis]
59 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
60 M Cunha G, Fowler KJ, Roudenko A, Taouli B, Fung AW, Elsayes KM, Marks RM, Cruite I, Horvat N, Chernyak V, Sirlin CB, Tang A. How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics 2021;41:1352-67. [PMID: 34297631 DOI: 10.1148/rg.2021200205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Qiu Y, Huang D, Sheng Y, Huang J, Li N, Zhang S, Hong Z, Yin X, Yan J. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1. Exp Cell Res 2021;405:112646. [PMID: 34029571 DOI: 10.1016/j.yexcr.2021.112646] [Reference Citation Analysis]
62 Zhou ZF, Peng F, Li JY, Ye YB. Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model. Onco Targets Ther 2019;12:7773-84. [PMID: 31571927 DOI: 10.2147/OTT.S222097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Wang X, Chen Y, Dong K, Ma Y, Jin Q, Yin S, Zhu X, Wang S. Effects of FER1L4-miR-106a-5p/miR-372-5p-E2F1 regulatory axis on drug resistance in liver cancer chemotherapy. Mol Ther Nucleic Acids 2021;24:449-61. [PMID: 33868788 DOI: 10.1016/j.omtn.2021.02.006] [Reference Citation Analysis]
64 Ismail IT, Fiehn O, Elfert A, Helal M, Salama I, El-Said H. Sugar Alcohols Have a Key Role in Pathogenesis of Chronic Liver Disease and Hepatocellular Carcinoma in Whole Blood and Liver Tissues. Cancers (Basel) 2020;12:E484. [PMID: 32092943 DOI: 10.3390/cancers12020484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
65 Wang SM, Yang PW, Feng XJ, Zhu YW, Qiu FJ, Hu XD, Zhang SH. Apigenin Inhibits the Growth of Hepatocellular Carcinoma Cells by Affecting the Expression of microRNA Transcriptome. Front Oncol 2021;11:657665. [PMID: 33959508 DOI: 10.3389/fonc.2021.657665] [Reference Citation Analysis]
66 Lewinska M, Santos-Laso A, Arretxe E, Alonso C, Zhuravleva E, Jimenez-Agüero R, Eizaguirre E, Pareja MJ, Romero-Gómez M, Jimenez MA, Suppli MP, Knop FK, Oversoe SK, Villadsen GE, Decaens T, Carrilho FJ, de Oliveira CP, Sangro B, Macias RIR, Banales JM, Andersen JB. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine 2021;73:103661. [PMID: 34740106 DOI: 10.1016/j.ebiom.2021.103661] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ma H, Huang C, Huang Q, Li G, Li J, Huang B, Zhong Q, Cao C. Circular RNA circ_0014717 Suppresses Hepatocellular Carcinoma Tumorigenesis Through Regulating miR-668-3p/BTG2 Axis. Front Oncol 2020;10:592884. [PMID: 33598424 DOI: 10.3389/fonc.2020.592884] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
68 Hussain Z, Rahim MA, Jan N, Shah H, Rawas-Qalaji M, Khan S, Sohail M, Thu HE, Ramli NA, Sarfraz RM, Abourehab MAS. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy. J Control Release 2021;335:130-57. [PMID: 34015400 DOI: 10.1016/j.jconrel.2021.05.018] [Reference Citation Analysis]
69 Zhang C, Wu J, Xu J, Xu J, Xian J, Xue S, Ye J. Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study. Dis Markers 2019;2019:2046825. [PMID: 31814857 DOI: 10.1155/2019/2046825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Zhu W, Doubleday PF, Butrin A, Weerawarna PM, Melani RD, Catlin DS, Dwight TA, Liu D, Kelleher NL, Silverman RB. Remarkable and Unexpected Mechanism for (S)-3-Amino-4-(difluoromethylenyl)cyclohex-1-ene-1-carboxylic Acid as a Selective Inactivator of Human Ornithine Aminotransferase. J Am Chem Soc 2021;143:8193-207. [PMID: 34014654 DOI: 10.1021/jacs.1c03572] [Reference Citation Analysis]
71 Qin B, Zeng Z, Xu J, Shangwen J, Ye ZJ, Wang S, Wu Y, Peng G, Wang Q, Gu W, Tang Y. Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and β-catenin. BMC Cancer 2022;22:671. [PMID: 35715752 DOI: 10.1186/s12885-022-09684-0] [Reference Citation Analysis]
72 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Mol Med Rep 2020;21:1849-60. [PMID: 32319631 DOI: 10.3892/mmr.2020.10991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
73 Flores BE, Fernandez AA, Wang CP, Bobadilla R, Hernandez L, Jain MK, Turner BJ. Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study. J Cancer Educ 2020. [PMID: 32588350 DOI: 10.1007/s13187-020-01805-2] [Reference Citation Analysis]
74 Yuan X, Yan Y, Xue M. Small nucleolar RNA host gene 8: A rising star in the targets for cancer therapy. Biomed Pharmacother 2021;139:111622. [PMID: 33894626 DOI: 10.1016/j.biopha.2021.111622] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Osna NA, Ganesan M, Seth D, Wyatt TA, Kidambi S, Kharbanda KK. Second hits exacerbate alcohol-related organ damage: an update. Alcohol Alcohol 2021;56:8-16. [PMID: 32869059 DOI: 10.1093/alcalc/agaa085] [Reference Citation Analysis]
76 Wang J, Huang Z, Lu H, Zhang R, Feng Q, He A, Kloczkowski A. A Pyroptosis-Related Gene Signature to Predict Patients’ Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma. Computational and Mathematical Methods in Medicine 2022;2022:1-17. [DOI: 10.1155/2022/1258480] [Reference Citation Analysis]
77 Molla MD, Dessie G, Akalu Y, Ayelign B. Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective. Int J Hepatol 2020;2020:2374615. [PMID: 32607257 DOI: 10.1155/2020/2374615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
78 Zhang S, Chen ZW, Meng SM, Ding QL, Zhong ZB, Wei YH, Ye QF, Hu KH. Eukaryotic initiation factor 3e subunit is positively associated with tumorigenesis and development of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2020; 28(12): 475-485 [DOI: 10.11569/wcjd.v28.i12.475] [Reference Citation Analysis]
79 Ryoo BY, Cheng AL, Ren Z, Kim TY, Pan H, Rau KM, Choi HJ, Park JW, Kim JH, Yen CJ, Lim HY, Zhou D, Straub J, Scheele J, Berghoff K, Qin S. Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. Br J Cancer 2021;125:200-8. [PMID: 33972742 DOI: 10.1038/s41416-021-01380-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Wu Q, Liu TY, Hu BC, Li X, Wu YT, Sun XT, Jiang XW, Wang S, Qin XC, Ding HW, Zhao QC. CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways. Front Oncol 2021;11:717626. [PMID: 34395292 DOI: 10.3389/fonc.2021.717626] [Reference Citation Analysis]
81 Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. Hepatol Commun 2020;4:1769-80. [PMID: 33305148 DOI: 10.1002/hep4.1599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
82 Liu T, Song C, Zhang Y, Siyin ST, Zhang Q, Song M, Cao L, Shi H. Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: A prospective cohort study. Int J Cancer 2021. [PMID: 34855203 DOI: 10.1002/ijc.33891] [Reference Citation Analysis]
83 Li Q, Xu H, Sui C, Zhang H. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. Clin Res Hepatol Gastroenterol 2021;:101781. [PMID: 34332136 DOI: 10.1016/j.clinre.2021.101781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol 2021;10:12. [PMID: 32527116 DOI: 10.21037/cco-20-113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
85 Yu MH, Tsai MC, Wang CC, Wu SW, Chang YJ, Wu CH, Wang CJ. Mulberry Leaf Polyphenol Extract and Rutin Induces Autophagy Regulated by p53 in Human Hepatoma HepG2 Cells. Pharmaceuticals (Basel) 2021;14:1310. [PMID: 34959709 DOI: 10.3390/ph14121310] [Reference Citation Analysis]
86 Liang L, Zhao L, Wang Y, Wang Y. Treatment for Hepatocellular Carcinoma Is Enhanced When Norcantharidin Is Encapsulated in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells. Mol Pharm 2021;18:1003-13. [PMID: 33527831 DOI: 10.1021/acs.molpharmaceut.0c00976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Murtha-Lemekhova A, Fuchs J, Schulz E, Sterkenburg AS, Mayer P, Pfeiffenberger J, Hoffmann K. Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features. J Hepatocell Carcinoma 2021;8:1269-79. [PMID: 34712626 DOI: 10.2147/JHC.S328198] [Reference Citation Analysis]
88 Aydin Y, Kurt R, Song K, Lin D, Osman H, Youngquist B, Scott JW, Shores NJ, Thevenot P, Cohen A, Dash S. Hepatic Stress Response in HCV Infection Promotes STAT3-Mediated Inhibition of HNF4A-miR-122 Feedback Loop in Liver Fibrosis and Cancer Progression. Cancers (Basel) 2019;11:E1407. [PMID: 31547152 DOI: 10.3390/cancers11101407] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
89 Lee HW, Cho KJ, Shin SY, Kim HY, Lee EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han K. Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. J Liver Cancer 2019;19:108-16. [DOI: 10.17998/jlc.19.2.108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
90 Asgharzadeh F, Jafarzadeh-esfehani R, Hassanian SM, Ferns GA, Avan A, Khazaei M. Renin-angiotensin System Inhibitors and Development of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. CPD 2020;26:5079-85. [DOI: 10.2174/1381612826666200713165018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Liu Z, Yu Y, Huang Z, Kong Y, Hu X, Xiao W, Quan J, Fan X. CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression. Cell Death Dis 2019;10:900. [PMID: 31776329 DOI: 10.1038/s41419-019-2089-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 68] [Article Influence: 18.0] [Reference Citation Analysis]
92 Javanmard D, Najafi M, Babaei MR, Karbalaie Niya MH, Esghaei M, Panahi M, Safarnezhad Tameshkel F, Tavakoli A, Jazayeri SM, Ghaffari H, Ataei-Pirkooh A, Monavari SH, Bokharaei-Salim F. Investigation of CTNNB1 gene mutations and expression in hepatocellular carcinoma and cirrhosis in association with hepatitis B virus infection. Infect Agent Cancer 2020;15:37. [PMID: 32514293 DOI: 10.1186/s13027-020-00297-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
93 Ganesan M, Mathews S, Makarov E, Petrosyan A, Kharbanda KK, Kidambi S, Poluektova LY, Casey CA, Osna NA. Acetaldehyde suppresses HBV-MHC class I complex presentation on hepatocytes via induction of ER stress and Golgi fragmentation. Am J Physiol Gastrointest Liver Physiol 2020;319:G432-42. [PMID: 32755306 DOI: 10.1152/ajpgi.00109.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
94 Li B, Jiang Y, Chu J, Zhou Q. Drug-Target Interaction Network Analysis of Gene-Phenotype Connectivity Maintained by Genistein. J Comput Biol 2020;27:1678-87. [PMID: 32298608 DOI: 10.1089/cmb.2019.0443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Coral GP, Branco F, Meurer R, Marcon PDS, Fontes PRO, Mattos AA. RESULTS OF IMMUNOHISTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF EARLY HEPATOCELLULAR CARCINOMA AND NODULES WITH HIGH-GRADE DYSPLASIA IN PATIENTS WITH CIRRHOSIS. Arq Gastroenterol 2021;58:82-6. [PMID: 33909802 DOI: 10.1590/S0004-2803.202100000-14] [Reference Citation Analysis]
96 Wang T, Zhang KH. New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol 2020;10:1316. [PMID: 32923383 DOI: 10.3389/fonc.2020.01316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
97 Ni C, Yang S, Ji Y, Duan Y, Yang W, Yang X, Li M, Xie J, Zhang C, Lu Y, Lu H. Hsa_circ_0011385 knockdown represses cell proliferation in hepatocellular carcinoma. Cell Death Discov 2021;7:270. [PMID: 34599150 DOI: 10.1038/s41420-021-00664-0] [Reference Citation Analysis]
98 Farghaly ME, Khowailed AA, Aboulhoda BE, Rashed LA, Gaber SS, Ashour H. Thymoquinone Potentiated the Anticancer Effect of Cisplatin on Hepatic Tumorigenesis by Modulating Tissue Oxidative Stress and Endoplasmic GRP78/CHOP Signaling. Nutr Cancer 2021;:1-10. [PMID: 33533291 DOI: 10.1080/01635581.2021.1879880] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Lv B, Liu X, Zhu X, Huang M. miR-382-5p promotes cell invasion in hepatocellular carcinoma by targeting PTEN to activate PI3K/Akt signaling pathway. World J Surg Oncol 2022;20:175. [PMID: 35655254 DOI: 10.1186/s12957-022-02638-7] [Reference Citation Analysis]
100 Paik JM, Golabi P, Biswas R, Alqahtani S, Venkatesan C, Younossi ZM. Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States. Hepatol Commun 2020;4:890-903. [PMID: 32490324 DOI: 10.1002/hep4.1510] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
101 Shen Y, Yang F, Peng H, Zhang G, Zhu F, Xu H, Shi L. Anti-tumor effect of Yanggan Huayu granule by inducing AKT-mediated apoptosis in hepatocellular carcinoma. J Ethnopharmacol 2022;282:114601. [PMID: 34487847 DOI: 10.1016/j.jep.2021.114601] [Reference Citation Analysis]
102 Tang Y, Chen J, Li J, Zheng Y, Zhong X, Huang S, Chen B, Peng B, Zou X, Chen X. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway. Phytomedicine 2021;86:153563. [PMID: 33951569 DOI: 10.1016/j.phymed.2021.153563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
104 Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:171. [PMID: 32185125 DOI: 10.3389/fonc.2020.00171] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
105 Elnagdy M, Barve S, McClain C, Gobejishvili L. cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease. Biomolecules 2020;10:E1433. [PMID: 33050657 DOI: 10.3390/biom10101433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Kant R, Yang MH, Tseng CH, Yen CH, Li WY, Tyan YC, Chen M, Tzeng CC, Chen WC, You K, Wang WC, Chen YL, Chen YA. Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structure-Activity Relationship Analysis. J Med Chem 2021;64:8992-9009. [PMID: 34132534 DOI: 10.1021/acs.jmedchem.1c00093] [Reference Citation Analysis]
107 Peisen F, Maurer M, Grosse U, Nikolaou K, Syha R, Artzner C, Bitzer M, Horger M, Grözinger G. Intraprocedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone. Eur J Radiol 2021;140:109768. [PMID: 33991970 DOI: 10.1016/j.ejrad.2021.109768] [Reference Citation Analysis]
108 Lv X, Xiang X, Wu Y, Liu Y, Xu R, Xiang Q, Lai G. GATA binding protein 4 promotes the expression and transcription of hepatitis B virus by facilitating hepatocyte nuclear factor 4 alpha in vitro. Virol J 2021;18:196. [PMID: 34583732 DOI: 10.1186/s12985-021-01668-z] [Reference Citation Analysis]
109 Yang PW, Chen TT, Zhao WX, Liu GW, Feng XJ, Wang SM, Pan YC, Wang Q, Zhang SH. Scutellaria barbata D.Don and Oldenlandia diffusa (Willd.) Roxb crude extracts inhibit hepatitis-B-virus-associated hepatocellular carcinoma growth through regulating circRNA expression. J Ethnopharmacol 2021;275:114110. [PMID: 33864890 DOI: 10.1016/j.jep.2021.114110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Zhu W, Doubleday PF, Catlin DS, Weerawarna PM, Butrin A, Shen S, Wawrzak Z, Kelleher NL, Liu D, Silverman RB. A Remarkable Difference That One Fluorine Atom Confers on the Mechanisms of Inactivation of Human Ornithine Aminotransferase by Two Cyclohexene Analogues of γ-Aminobutyric Acid. J Am Chem Soc 2020;142:4892-903. [PMID: 32114761 DOI: 10.1021/jacs.0c00193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
111 Huang Y, Zhang C, Xiong J, Ren H. Emerging important roles of circRNAs in human cancer and other diseases. Genes Dis 2021;8:412-23. [PMID: 34179306 DOI: 10.1016/j.gendis.2020.07.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
112 Yang J, Xing Z. Ligustilide counteracts carcinogenesis and hepatocellular carcinoma cell-evoked macrophage M2 polarization by regulating yes-associated protein-mediated interleukin-6 secretion. Exp Biol Med (Maywood) 2021;246:1928-37. [PMID: 34053234 DOI: 10.1177/15353702211010420] [Reference Citation Analysis]
113 Huo J, Fan X, Qi B, Sun P. A Five-Gene Signature Associated With DNA Damage Repair Molecular Subtype Predict Overall Survival for Hepatocellular Carcinoma. Front Genet 2022;13:771819. [DOI: 10.3389/fgene.2022.771819] [Reference Citation Analysis]
114 Yamaguchi M, Murata T, Ramos JW. The calcium channel agonist Bay K 8644 promotes the growth of human liver cancer HepG2 cells in vitro: suppression with overexpressed regucalcin. Mol Cell Biochem 2020;472:173-85. [PMID: 32591915 DOI: 10.1007/s11010-020-03795-7] [Reference Citation Analysis]
115 Gersten O, Barbieri M. Evaluation of the Cancer Transition Theory in the US, Select European Nations, and Japan by Investigating Mortality of Infectious- and Noninfectious-Related Cancers, 1950-2018. JAMA Netw Open 2021;4:e215322. [PMID: 33843999 DOI: 10.1001/jamanetworkopen.2021.5322] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. Ann Hepatol 2021;27:100556. [PMID: 34800721 DOI: 10.1016/j.aohep.2021.100556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]